
Global Virus like Particle (VLP) Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Virus like Particle (VLP) Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Virus like Particle (VLP) Vaccines include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Virus like Particle (VLP) Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Virus like Particle (VLP) Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Virus like Particle (VLP) Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Virus like Particle (VLP) Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Virus like Particle (VLP) Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Virus like Particle (VLP) Vaccines sales, projected growth trends, production technology, application and end-user industry.
Virus like Particle (VLP) Vaccines Segment by Company
WuXi Biologics
Junshi Biosciences
Luye Pharma Group
Chengdu Kanghua Biological Products Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.
VBI Vaccines Inc
Premas Biotech
Creative Diagnostics
Creative Biostructure
Coriolis
Charles River Laboratories
BioAgilytix
AstraZeneca Group (Icosavax)
Virus like Particle (VLP) Vaccines Segment by Type
Prophylactic Vaccine
Therapeutic Vaccine
Virus like Particle (VLP) Vaccines Segment by Application
Human Papillomavirus (HPV)
Hepatitis E Virus (HEV)
Hepatitis B Virus (HBV)
Other
Virus like Particle (VLP) Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Virus like Particle (VLP) Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Virus like Particle (VLP) Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Virus like Particle (VLP) Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Virus like Particle (VLP) Vaccines include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Virus like Particle (VLP) Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Virus like Particle (VLP) Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Virus like Particle (VLP) Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Virus like Particle (VLP) Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Virus like Particle (VLP) Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Virus like Particle (VLP) Vaccines sales, projected growth trends, production technology, application and end-user industry.
Virus like Particle (VLP) Vaccines Segment by Company
WuXi Biologics
Junshi Biosciences
Luye Pharma Group
Chengdu Kanghua Biological Products Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.
VBI Vaccines Inc
Premas Biotech
Creative Diagnostics
Creative Biostructure
Coriolis
Charles River Laboratories
BioAgilytix
AstraZeneca Group (Icosavax)
Virus like Particle (VLP) Vaccines Segment by Type
Prophylactic Vaccine
Therapeutic Vaccine
Virus like Particle (VLP) Vaccines Segment by Application
Human Papillomavirus (HPV)
Hepatitis E Virus (HEV)
Hepatitis B Virus (HBV)
Other
Virus like Particle (VLP) Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Virus like Particle (VLP) Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
196 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Virus like Particle (VLP) Vaccines Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Virus like Particle (VLP) Vaccines Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Virus like Particle (VLP) Vaccines Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Virus like Particle (VLP) Vaccines Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Virus like Particle (VLP) Vaccines Market Dynamics
- 2.1 Virus like Particle (VLP) Vaccines Industry Trends
- 2.2 Virus like Particle (VLP) Vaccines Industry Drivers
- 2.3 Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges
- 2.4 Virus like Particle (VLP) Vaccines Industry Restraints
- 3 Virus like Particle (VLP) Vaccines Market by Manufacturers
- 3.1 Global Virus like Particle (VLP) Vaccines Revenue by Manufacturers (2020-2025)
- 3.2 Global Virus like Particle (VLP) Vaccines Sales by Manufacturers (2020-2025)
- 3.3 Global Virus like Particle (VLP) Vaccines Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Virus like Particle (VLP) Vaccines Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Virus like Particle (VLP) Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Virus like Particle (VLP) Vaccines Manufacturers, Product Type & Application
- 3.7 Global Virus like Particle (VLP) Vaccines Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Virus like Particle (VLP) Vaccines Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Virus like Particle (VLP) Vaccines Players Market Share by Revenue in 2024
- 3.8.3 2024 Virus like Particle (VLP) Vaccines Tier 1, Tier 2, and Tier 3
- 4 Virus like Particle (VLP) Vaccines Market by Type
- 4.1 Virus like Particle (VLP) Vaccines Type Introduction
- 4.1.1 Prophylactic Vaccine
- 4.1.2 Therapeutic Vaccine
- 4.2 Global Virus like Particle (VLP) Vaccines Sales by Type
- 4.2.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Virus like Particle (VLP) Vaccines Sales by Type (2020-2031)
- 4.2.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2020-2031)
- 4.3 Global Virus like Particle (VLP) Vaccines Revenue by Type
- 4.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2020-2031)
- 4.3.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2020-2031)
- 5 Virus like Particle (VLP) Vaccines Market by Application
- 5.1 Virus like Particle (VLP) Vaccines Application Introduction
- 5.1.1 Human Papillomavirus (HPV)
- 5.1.2 Hepatitis E Virus (HEV)
- 5.1.3 Hepatitis B Virus (HBV)
- 5.1.4 Other
- 5.2 Global Virus like Particle (VLP) Vaccines Sales by Application
- 5.2.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Virus like Particle (VLP) Vaccines Sales by Application (2020-2031)
- 5.2.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2020-2031)
- 5.3 Global Virus like Particle (VLP) Vaccines Revenue by Application
- 5.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2020-2031)
- 5.3.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2020-2031)
- 6 Global Virus like Particle (VLP) Vaccines Sales by Region
- 6.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Virus like Particle (VLP) Vaccines Sales by Region (2020-2031)
- 6.2.1 Global Virus like Particle (VLP) Vaccines Sales by Region (2020-2025)
- 6.2.2 Global Virus like Particle (VLP) Vaccines Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Virus like Particle (VLP) Vaccines Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Virus like Particle (VLP) Vaccines Revenue by Region
- 7.1 Global Virus like Particle (VLP) Vaccines Revenue by Region
- 7.1.1 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Virus like Particle (VLP) Vaccines Revenue by Region (2020-2025)
- 7.1.3 Global Virus like Particle (VLP) Vaccines Revenue by Region (2026-2031)
- 7.1.4 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Virus like Particle (VLP) Vaccines Revenue (2020-2031)
- 7.2.2 North America Virus like Particle (VLP) Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Virus like Particle (VLP) Vaccines Revenue (2020-2031)
- 7.3.2 Europe Virus like Particle (VLP) Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Virus like Particle (VLP) Vaccines Revenue (2020-2031)
- 7.4.2 Asia-Pacific Virus like Particle (VLP) Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 WuXi Biologics
- 8.1.1 WuXi Biologics Comapny Information
- 8.1.2 WuXi Biologics Business Overview
- 8.1.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
- 8.1.5 WuXi Biologics Recent Developments
- 8.2 Junshi Biosciences
- 8.2.1 Junshi Biosciences Comapny Information
- 8.2.2 Junshi Biosciences Business Overview
- 8.2.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
- 8.2.5 Junshi Biosciences Recent Developments
- 8.3 Luye Pharma Group
- 8.3.1 Luye Pharma Group Comapny Information
- 8.3.2 Luye Pharma Group Business Overview
- 8.3.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
- 8.3.5 Luye Pharma Group Recent Developments
- 8.4 Chengdu Kanghua Biological Products Co., Ltd.
- 8.4.1 Chengdu Kanghua Biological Products Co., Ltd. Comapny Information
- 8.4.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
- 8.4.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
- 8.4.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
- 8.5 Shanghai Bovax Biotechnology Co., Ltd.
- 8.5.1 Shanghai Bovax Biotechnology Co., Ltd. Comapny Information
- 8.5.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
- 8.5.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
- 8.5.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
- 8.6 VBI Vaccines Inc
- 8.6.1 VBI Vaccines Inc Comapny Information
- 8.6.2 VBI Vaccines Inc Business Overview
- 8.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
- 8.6.5 VBI Vaccines Inc Recent Developments
- 8.7 Premas Biotech
- 8.7.1 Premas Biotech Comapny Information
- 8.7.2 Premas Biotech Business Overview
- 8.7.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
- 8.7.5 Premas Biotech Recent Developments
- 8.8 Creative Diagnostics
- 8.8.1 Creative Diagnostics Comapny Information
- 8.8.2 Creative Diagnostics Business Overview
- 8.8.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
- 8.8.5 Creative Diagnostics Recent Developments
- 8.9 Creative Biostructure
- 8.9.1 Creative Biostructure Comapny Information
- 8.9.2 Creative Biostructure Business Overview
- 8.9.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
- 8.9.5 Creative Biostructure Recent Developments
- 8.10 Coriolis
- 8.10.1 Coriolis Comapny Information
- 8.10.2 Coriolis Business Overview
- 8.10.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
- 8.10.5 Coriolis Recent Developments
- 8.11 Charles River Laboratories
- 8.11.1 Charles River Laboratories Comapny Information
- 8.11.2 Charles River Laboratories Business Overview
- 8.11.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
- 8.11.5 Charles River Laboratories Recent Developments
- 8.12 BioAgilytix
- 8.12.1 BioAgilytix Comapny Information
- 8.12.2 BioAgilytix Business Overview
- 8.12.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
- 8.12.5 BioAgilytix Recent Developments
- 8.13 AstraZeneca Group (Icosavax)
- 8.13.1 AstraZeneca Group (Icosavax) Comapny Information
- 8.13.2 AstraZeneca Group (Icosavax) Business Overview
- 8.13.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
- 8.13.5 AstraZeneca Group (Icosavax) Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Virus like Particle (VLP) Vaccines Value Chain Analysis
- 9.1.1 Virus like Particle (VLP) Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Virus like Particle (VLP) Vaccines Production Mode & Process
- 9.2 Virus like Particle (VLP) Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Virus like Particle (VLP) Vaccines Distributors
- 9.2.3 Virus like Particle (VLP) Vaccines Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.